A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 26,800 shares of PRCT stock, worth $2.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,800
Previous 36,400 26.37%
Holding current value
$2.24 Million
Previous $2.22 Million 3.46%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.31 - $84.99 $913,179 - $1.38 Million
16,217 Added 59.19%
43,617 $3.49 Million
Q2 2024

Aug 14, 2024

BUY
$45.73 - $69.19 $419,618 - $634,887
9,176 Added 50.35%
27,400 $1.67 Million
Q1 2024

May 15, 2024

SELL
$40.38 - $50.75 $9.59 Million - $12.1 Million
-237,483 Reduced 92.87%
18,224 $900,000
Q4 2023

Feb 14, 2024

SELL
$24.89 - $43.41 $21.4 Million - $37.3 Million
-858,580 Reduced 77.05%
255,707 $10.7 Million
Q3 2023

Nov 14, 2023

BUY
$30.02 - $38.81 $19.2 Million - $24.8 Million
638,676 Added 134.29%
1,114,287 $36.6 Million
Q2 2023

Aug 14, 2023

SELL
$26.7 - $37.02 $13.2 Million - $18.3 Million
-494,029 Reduced 50.95%
475,611 $16.8 Million
Q1 2023

May 15, 2023

BUY
$26.64 - $39.74 $7.99 Million - $11.9 Million
299,950 Added 44.79%
969,640 $27.5 Million
Q4 2022

Feb 14, 2023

BUY
$38.78 - $46.78 $18 Million - $21.8 Million
465,055 Added 227.26%
669,690 $27.8 Million
Q3 2022

Nov 14, 2022

SELL
$30.9 - $50.65 $3.28 Million - $5.38 Million
-106,248 Reduced 34.18%
204,635 $8.48 Million

Others Institutions Holding PRCT

About PROCEPT BioRobotics Corp


  • Ticker PRCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 44,592,300
  • Market Cap $3.73B
  • Description
  • PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...
More about PRCT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.